Study identifier:9393IL/0028
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized Clinical Trial Comparing Goserelin Acetate (ZOLADEX tm) 3.6-mg Depot and Goserelin Acetate (Zoladex) 10.8-MG Depot in Subjects with Prostate Cancer for Whom Hormonal Therapy is Indicated
prostate cancer
Phase 4
-
-
-
-
Interventional
-
Allocation: - 
Endpoint Classification: - 
Intervention Model: - 
Masking: - 
Primary Purpose: - 
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|